Taken together, the data from the current trial demonstrates that high lysine transgenic rice led to no adverse effect in Sprague-Dawley rats given a diet containing up to 70% HFL1 rice in 90 days.
However, if the current trial demonstrates that there is no additional benefit from early physiotherapy, this would provide the rationale (and the ethical justification) for randomised trials of specific physiotherapeutic modalities.
This approach can be used to explicitly demonstrate how current trial evidence applies to different patient subgroups, and allows this evidence to be combined with subjective patient-rated preferences (utilities; Drummond et al, 2005) and the financial implications of treatment strategies.
The primary tumour location as well as the basic demographic characteristics of the patients who participated at the current trial is demonstrated in Table 1.
The current multicenter phase II trial demonstrated that the three-drug combination of bevacizumab, L-OHP and 5-FU/LV produced a high response rate (67.9%) with a median duration of response of 7 months and a median TTP of 11 months.
The current single-institution randomised phase II trial demonstrated that the XELIRI regimen is effective in the neoadjuvant treatment of patients with MCRC and that it has acceptable toxicity, when compared to the FOLFIRI regimen.
The current Phase Ib trial demonstrates that AZD0530 is generally safe and well tolerated in patients with AD, with oral dosing yielding excellent CNS drug concentration.
The current randomized controlled trial demonstrates that CFQ, a particular form of qigong, is potentially a useful self-care practice for individuals with fibromyalgia.
Trial demonstrated it increased clothing sales 3 times and dramatically reduced returns by 28%.
The firm behind it, Ethertronics, is already using this "active steering" principle to improve mobile-phone signals, and wi-fi is an extension of that work; current trials apparently demonstrate an increase of between 20 and 45 per cent in signal strength.
